ASX Releases

June 2010	BPH Corporate Update on the HLS5 Tumor Suppressor Gene
November 2009	Hls5 to be presented at the 51st ASH Annual Meeting
November 2009	NHMRC $608,500 Grant for HLS5
August 2009	US Patent Granted for HLS5
May 2009	HLS5 Project Awarded Grant for Melanoma Research
February 2009	HLS5 presented at the 21st Lorne Cancer Conference 2009
September 2008	HLS5 at BIO2008
September 2008	HLS5 Presented at ComBio 2008 in Canberra
September 2008	New Drug - Cancer Impact
July 2008	Genes Identified in a Hemopoietic Lineage Switch Influence Transcription
June 2008	HLS5 Screening yields New Drug Leads
May 2008	HLS5 Conference Coverage - Leave it to the Master Gene
February 2008	International HLS5 Scientific Publication
June 2007	BioPharmica to move to 83.5% in HLS5 investment
May 2007	BioPharmica Limited Joint Venture Patents as at 7 May 2007
May 2007	HLS5 Tumour Suppressor Gene - Developments Update
October 2006	BioPharmica in GE Healthcare Collaboration
September 2006	BPH secures "Tumour Suppressor Factor" Patent number 784629
January 2006	HLS5 Gene implicated in Huntington's and AIDS
September 2005	HLS5 Gene Project Update
May 2005	Successful HLS5 Cancer Gene Pre-clinical Trial
February 2005	BioPharmica Cancer Gene Pilot Trial
January 2005	Cancer expert joins BioPharmica HLS5 Reserach Team
September 2004	BioPharmica Cancer Gene Progress